Literature DB >> 14645636

Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.

Arlene A Forastiere1, Helmuth Goepfert, Moshe Maor, Thomas F Pajak, Randal Weber, William Morrison, Bonnie Glisson, Andy Trotti, John A Ridge, Clifford Chao, Glen Peters, Ding-Jen Lee, Andrea Leaf, John Ensley, Jay Cooper.   

Abstract

BACKGROUND: Induction chemotherapy with cisplatin plus fluorouracil followed by radiotherapy is the standard alternative to total laryngectomy for patients with locally advanced laryngeal cancer. The value of adding chemotherapy to radiotherapy and the optimal timing of chemotherapy are unknown.
METHODS: We randomly assigned patients with locally advanced cancer of the larynx to one of three treatments: induction cisplatin plus fluorouracil followed by radiotherapy, radiotherapy with concurrent administration of cisplatin, or radiotherapy alone. The primary end point was preservation of the larynx.
RESULTS: A total of 547 patients were randomly assigned to one of the three study groups. The median follow-up period was 3.8 years. At two years, the proportion of patients who had an intact larynx after radiotherapy with concurrent cisplatin (88 percent) differed significantly from the proportions in the groups given induction chemotherapy followed by radiotherapy (75 percent, P=0.005) or radiotherapy alone (70 percent, P<0.001). The rate of locoregional control was also significantly better with radiotherapy and concurrent cisplatin (78 percent, vs. 61 percent with induction cisplatin plus fluorouracil followed by radiotherapy and 56 percent with radiotherapy alone). Both of the chemotherapy-based regimens suppressed distant metastases and resulted in better disease-free survival than radiotherapy alone. However, overall survival rates were similar in all three groups. The rate of high-grade toxic effects was greater with the chemotherapy-based regimens (81 percent with induction cisplatin plus fluorouracil followed by radiotherapy and 82 percent with radiotherapy with concurrent cisplatin, vs. 61 percent with radiotherapy alone). The mucosal toxicity of concurrent radiotherapy and cisplatin was nearly twice as frequent as the mucosal toxicity of the other two treatments during radiotherapy.
CONCLUSIONS: In patients with laryngeal cancer, radiotherapy with concurrent administration of cisplatin is superior to induction chemotherapy followed by radiotherapy or radiotherapy alone for laryngeal preservation and locoregional control. Copyright 2003 Massachusetts Medical Society

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14645636     DOI: 10.1056/NEJMoa031317

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  648 in total

1.  Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.

Authors:  Phuc Felix Nguyen-Tan; Qiang Zhang; K Kian Ang; Randal S Weber; David I Rosenthal; Denis Soulieres; Harold Kim; Craig Silverman; Adam Raben; Thomas J Galloway; André Fortin; Elizabeth Gore; William H Westra; Christine H Chung; Richard C Jordan; Maura L Gillison; Marcie List; Quynh-Thu Le
Journal:  J Clin Oncol       Date:  2014-11-03       Impact factor: 44.544

2.  Functional outcome after different oncological interventions in head and neck cancer patients.

Authors:  Thomas Mücke; Janett Koschinski; Stefan Wagenpfeil; Klaus-Dietrich Wolff; Anastasios Kanatas; David A Mitchell; Herbert Deppe; Marco R Kesting
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-06       Impact factor: 4.553

3.  Hangeshashinto (TJ-14) prevents radiation-induced mucositis by suppressing cyclooxygenase-2 expression and chemotaxis of inflammatory cells.

Authors:  D Kamide; T Yamashita; K Araki; M Tomifuji; A Shiotani
Journal:  Clin Transl Oncol       Date:  2017-05-17       Impact factor: 3.405

4.  The evaluation of esophageal adenocarcinoma using dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Eugene Y Chang; Xin Li; Michael Jerosch-Herold; Ryan A Priest; C Kristian Enestvedt; Jingang Xu; Charles S Springer; Blair A Jobe
Journal:  J Gastrointest Surg       Date:  2007-09-01       Impact factor: 3.452

5.  Akt activation synergizes with Trp53 loss in oral epithelium to produce a novel mouse model for head and neck squamous cell carcinoma.

Authors:  Marta Moral; Carmen Segrelles; M Fernanda Lara; Ana Belén Martínez-Cruz; Corina Lorz; Mirentxu Santos; Ramón García-Escudero; Jerry Lu; Kaoru Kiguchi; Agueda Buitrago; Clotilde Costa; Cristina Saiz; Jose L Rodriguez-Peralto; Francisco J Martinez-Tello; Maria Rodriguez-Pinilla; Montserrat Sanchez-Cespedes; Marina Garín; Teresa Grande; Ana Bravo; John DiGiovanni; Jesús M Paramio
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

6.  Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy.

Authors:  J L Lefebvre; F Rolland; M Tesselaar; E Bardet; C R Leemans; L Geoffrois; P Hupperets; L Barzan; D de Raucourt; D Chevalier; L Licitra; F Lunghi; R Stupp; D Lacombe; J Bogaerts; J C Horiot; J Bernier; J B Vermorken
Journal:  J Natl Cancer Inst       Date:  2009-01-27       Impact factor: 13.506

7.  Squamous cell carcinoma of the larynx with subglottic extension: is larynx preservation possible?

Authors:  A Levy; P Blanchard; S Temam; M-M Maison; F Janot; H Mirghani; F Bidault; J Guigay; A Lusinchi; J Bourhis; N Daly-Schveitzer; Y Tao
Journal:  Strahlenther Onkol       Date:  2014-03-04       Impact factor: 3.621

Review 8.  Recent Landmark Studies on Head and Neck Cancers: Evidence-Based Fundamentals of Modern Therapeutic Approaches.

Authors:  Utku Aydil
Journal:  Turk Arch Otorhinolaryngol       Date:  2015-03-01

9.  Locally advanced laryngeal cancer: Total laryngectomy or primary non-surgical treatment?

Authors:  Aleš Čoček; Miloslav Ambruš; Alena Dohnalová; Martin Chovanec; Martina Kubecová; Kateřina Licková
Journal:  Oncol Lett       Date:  2018-03-01       Impact factor: 2.967

10.  Age-adjusted comorbidity and survival in locally advanced laryngeal cancer.

Authors:  Collin F Mulcahy; Abdallah S R Mohamed; Aasheesh Kanwar; Katherine A Hutcheson; Alokananda Ghosh; David Vock; Randal S Weber; Stephen Y Lai; Gary Brandon Gunn; Mark Zafereo; William H Morrison; Renata Ferrarotto; Adam S Garden; David I Rosenthal; Clifton D Fuller
Journal:  Head Neck       Date:  2018-05-13       Impact factor: 3.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.